Company / R&D Expense
Viridian Therapeutics, Inc.\DE R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$338.9M
FY2025
5-year range
$56.9M / $338.9M
FY2021-FY2025
Trend
+42.3%
vs FY2024
Sector context
#52 of 210
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's r&d expense of $339M is higher than 75% of companies in the Health Care sector (FY2025). R&D Expense has increased for 5 consecutive years, from $28M in FY2020 to $339M in FY2025.
Based on SEC 10-K filings.
$339M in FY2025 with a 5-year CAGR of +64.3%. Top quartile in the Health Care sector.
Improved from $160M to $339M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +49.8%
- 5-Year CAGR
- +64.3%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 210This company $338.9M Sector average $644.1M
▼
-47.4% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +64.3%, indicating consistent growth.
- In FY2025, r&d expense increased 42.3% year-over-year.
- Ranks #52 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $338.9M | +42.3% |
| FY2024 | $238.3M | +49.1% |
| FY2023 | $159.8M | +58.3% |
| FY2022 | $100.9M | +77.4% |
| FY2021 | $56.9M | +101.0% |
| FY2020 | $28.3M | -18.7% |
| FY2019 | $34.8M | +14.4% |
| FY2018 | $30.4M | +55.0% |
| FY2017 | $19.6M | +43.3% |
| FY2016 | $13.7M | +1266.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026